• Like
  • Save
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutical Patent Attorney -- Resume and Curriculum Vitae
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutical Patent Attorney -- Resume and Curriculum Vitae

  • 255 views
Published

This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.

This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.

Published in Technology
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
255
On SlideShare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Gary M. Myles, Ph.D. MERCHANT & GOULD COLUMBIA CENTER • 701 FIFTH AVENUE, SUITE 4100 • SEATTLE, WA 98104-7073 Direct 206.342.6226 • Mobile 425.466.8262 • gmyles@merchantgould.comEDUCATIONUniversity of Washington School of Law//Seattle, Washington, J.D., June 1999University of North Carolina//Chapel Hill, North Carolina, Ph.D., Biochemistry and Biophysics, Dec. 1990University of Michigan//Ann Arbor, Michigan; course work, Chemical Engineering, 1981-1982 academic yearUniversity of Illinois//Urbana-Champaign, Illinois, B.S., Biochemistry, May 1981LEGAL EXPERIENCEMerchant & Gould//Seattle, WashingtonOf Counsel, January 2012 to presentLead biotechnology patent prosecutor in Seattle office with focus on biotechnology and medical device related patentstrategy and counseling, patent drafting and prosecution, and IP licensing, negotiation, and dispute resolution for startupand mid-size biotechnology companies, universities and non-profit research institutions, and large agriculturalbiotechnology companies. Manage complex biotechnology patent portfolios; render freedom-to-operate, non-infringement, and invalidity opinions; and perform intellectual property due diligence for transactions including M&A andventure financing.Schwabe, Williamson & Wyatt//Seattle, WashingtonShareholder, February 2009 to December 2011Lead biotechnology patent prosecutor in Seattle office with focus on biotechnology and medical device related patentstrategy and counseling, patent drafting and prosecution, and IP licensing, negotiation, and dispute resolution for startupand mid-size biotechnology companies, universities and non-profit research institutions, and large agriculturalbiotechnology companies. Managed complex biotechnology patent portfolios; rendered freedom-to-operate, non-infringement, and invalidity opinions; and performed intellectual property due diligence for transactions including M&Aand venture financing.Darby & Darby PC//Seattle, WashingtonAssociate Attorney, November 2005 to February 2009Provided patent counseling, patent application drafting, patent prosecution and related licensing, intellectualproperty portfolio evaluation and dispute resolution advice to life science clients. Formulated freedom-to-operate, non-infringement, and invalidity opinions and perform intellectual property due diligence reviews forclients in the biotechnology, biomedical device, and mechanical device industries. 2nd chair litigation oncomplex biotechnology patent dispute involving lentiviral vector technology.Speckman Law Group PLLC//Seattle, WashingtonPatent Attorney, June 2002 to November 2005Provided patent counseling, patent application drafting and prosecution, as well as related licensing, intellectualproperty portfolio evaluation and dispute resolution advice to technology clients. Formulated freedom-to-operate,non-infringement, and invalidity opinions and performed intellectual property due diligence reviews. Areas oftechnological expertise included molecular biology and biotechnology, biomedical devices and processes andmechanical technologies. Was actively involved in formulating intellectual property strategies and implementingthose strategies on a worldwide basis.Corixa Corporation//Seattle, WashingtonPatent Attorney, January 2001 to May 2002Oversaw major portion of U.S. and foreign patent portfolio. Drafted and prosecuted patent applications in areas oftumor antigen, infectious disease and autoimmune vaccines, therapeutics and diagnostics and direct outside counselin same. Researched and formulated patentability, freedom-to-operate and non-infringement opinions. Interfacedwith company scientists to identify new intellectual property and licensing opportunities. Worked with businessdevelopment group to facilitate patent in- and out-licensing. Reviewed company contracts for potential intellectual
  • 2. property and other legal issues. Met with corporate partners to discuss and develop patent strategies consistent withbusiness agreements.Seed Intellectual Property Law Group PLLC//Seattle, WashingtonChemical and Biotechnology Practice GroupAssociate Attorney, August 1999 to December 2000Law Clerk, April 1999 to July 1999• Prepared and prosecuted U.S. and foreign biotechnology patent applications for domestic and foreign clients• Researched and drafted patentability, freedom-to-operate and non-infringement opinions• Consulted with clients to develop strategies for obtaining patent protection consistent with business planTownsend & Townsend & Crew LLP//Seattle, WashingtonChemical and Biotechnology Practice GroupTechnical Advisor/Law Clerk, July 1996 to December 1998• Drafted and prosecuted biotechnology patent applications• Analyzed conception and reduction-to-practice in biotechnology patent interferences• Completed patent and prior art search for and draft of non-infringement and freedom-to-operate opinionsBAR ADMISSIONSWashington State Bar -- Active Member since November 22, 1999 (Bar No. 29,684)Registered to practice before the United States Patent and Trademark Office, 1999 (Registration No. 46,209)Registered to practice before the U.S. District Court for the Western District of Washington, 2000LAW SCHOOL TEACHING EXPERIENCESeattle University School of Law//Seattle, WashingtonAdjunct Professor of Law, March 2004 to present• Teach course “Biotechnology and the Law” with emphasis on the nexus between law, technology, and business• Coach new companies on developing business plans for and participate in SU business plan competitionUniversity of Washington School of Law//Seattle, WashingtonAdjunct Professor and Law, Technology & Arts Fellow, November 2002 to present• Teach course “Advanced Patent Law” to JD and LLM students• Mentor students in the preparation of research papers for LLM program• Coach new companies on developing business plans for and participate in UW business plan competitionUniversity of Illinois School of Law//Champaign-Urbana, IllinoisGuest Lecturer, October 2009 to present• Teach class on biotechnology patent law to JD students• Mentor students on career options for the professional life scientistHONORSSeattle IP Inn of CourtSeattle University School of Law and University of Washington Law School, 2010 to presentWashington Super LawyersWashington Law and Politics, 2010 and 2011Law, Technology & Arts FellowUniversity of Washington Law School
  • 3. LEGAL SEMINARS AND PUBLICATIONS“Patenting Human DNA, Embryos and Organs: Recent Case Law Developments in the United States”CASRIP High Technology Protection SummitUniversity of Washington School of Law, Seattle, WA//July 2012“America Invents Act: Recent Changes to the Patent Law”University of Washington School of Law, Seattle, WA//February 2012“Biotechnology: Technology, Role of Patents, and Patent Eligibility under 35 U.S.C. § 101”University of Washington School of Law, Seattle, WA//February 2012Participant in Panel Discussion on America Invents Act; “Immediate Impacts on Patent Transactions”Law Seminars International, Seattle, WA//January 2012“Recent Changes to U.S. Patent Law and How They Impact Patent Protection and Valuation”Licensing Executives Society, Seattle Chapter//November 2011Symposium Participant; “Establishing and Managing Cross-Institutional Research Collaborations”Presentation entitled “Recent Changes Impacting Patent Rights and IP Valuations in Inter-InstitutionalCollaborations”Annual Conference of Society of Research Administrators International, Montreal, Quebec//October 2011“Biotechnology: Technology, Role of Patents, and Patent Eligibility under 35 U.S.C. § 101”University of Illinois School of Law, Champaign, IL//October 2011Co-chair of Program Committee for Symposium “Patenting in the Biotechnology Industry: 30 Years afterDiamond v. Chakrabarty”University of Illinois, Champaign, IL//September 2010Schwabe, Williamson & Wyatt Career Seminar; “Career Options for the Professional Life Scientist”Fred Hutchinson Cancer Research Center, Seattle, WA//June 2010University of Illinois, Champaign, IL//September 2009Schwabe, Williamson & Wyatt IP Seminar; “Biotechnology Process Inventions: Patentable Subject Matterafter In Re Bilski”Seattle, WA//March 18, 2009Davison, E. M. and Myles, G.M., “How Biotech Patentees can Navigate KSR,” Managing Intellectual Property,79-82 (July/August 2008)Darby & Darby IP Seminar; “Inequitable Conduct and the Duty of Disclosure: The Road to Hell is Pavedwith Good Intentions”Vancouver, BC//December 5, 2008Darby & Darby IP Seminar; “Determining Obviousness after the Supreme Court Blast in KSR–-It’s Déjàvu all over Again”Seattle, WA//March 19, 2008Darby & Darby IP Seminar; “The Coming Change in U.S. Patent Law: Patent Reform Act of 2007”Vancouver, BC//December 3, 2007Darby & Darby IP Seminar; “Strategic Options in View of Recent Patent Case Law”Seattle, WA//March 21, 2007Presentation entitled “Challenging the Obviousness Standard: KSR v. TeleflexDarby & Darby IP Seminar; “Repelling the Invasion of the Patent Snatchers: Patent Strategies in View ofan Unpredictable Federal Circuit”Portland, OR//October 25, 2006
  • 4. Vancouver, BC//October 26, 2006Palo Alto, CA//November 7, 2006Seattle, WA//November 8, 2006Presentation entitled “Disappearance of the Continuation-in-Part: Chiron v. Genentech and Other Federal CircuitDecisions Alien to Traditional Patent PracticeDarby & Darby IP Seminar; “A Coming Sea Change in Patent Law: Are You Ready to Navigate thePerfect Storm?”Seattle, WA//March 22, 2006Presentation entitled “Preparing for Intellectual Property Due Diligence in Connection with Venture Financing”Lorman Educational ServicesOctober 21, 2003Seminar entitled “Management of Intellectual Property Documents”PRO BONOUniversity of Washington School of Law//Seattle, WAEntrepreneurial Law Clinic; 2005 to presentOversee student representation of clinic clients in matters relating to patents, trademarks, copyrights, and tradesecretsWashington Biotechnology and Biomedical Association//Seattle, WAInvest Northwest 2007Co-chair of Selection and Recruitment Committee for 2007 conference at Bell Harbor in Seattle, WAPROFESSIONAL AND COMMUNITY MEMBERSHIPSWashington State Bar AssociationAmerican Bar AssociationWashington State Patent Law AssociationAmerican Intellectual Property Law AssociationLicensing Executives SocietyAssociation of University Technology ManagersWashington Biotechnology and Biomedical AssociationSCIENTIFIC EXPERIENCEFred Hutchinson Cancer Research Center// Seattle, WashingtonBasic Sciences Division - Department of Cell BiologySenior Research Fellow, 1993-1996Training Grant #T32 CA09437 - University of Washington, Department of PathologyPostdoctoral Research Associate, 1990-1993• Researched the molecular mechanisms of signal transduction initiated by the c-fms protooncogene productexpressed in a murine myeloid cell line• Performed two-hybrid screening method to identify and clone cellular substrates of the c-Fms cytoplasmic domain• Identified sites of in vivo tyrosine autophosphorylation and assessed role of c-Fms phosphorylation in cellulardifferentiation and proliferation through construction and expression of site-directed c-Fms point mutants• Performed studies on the molecular mechanism of c-Fms M-CSF-dependent endocytosis and potential role incellular differentiation and proliferationUniversity of North Carolina//Chapel Hill, North CarolinaResearch Assistant, School of Medicine - Department of Biochemistry and Biophysics, 1984-1990Ph.D. Dissertation: “Structure-Function Studies on UvrA: An Escherichia coli DNA Repair Protein”• Performed experiments on the molecular mechanism of the E. coli UvrABC excinuclease DNA nucleotide excisionrepair complex• Created site-directed point mutants in conserved DNA-binding and ATPase active site residues of UvrA andassessed the effect of these mutations on DNA repair in vitro and in vivo
  • 5. • Prepared plasmid constructs expressing UvrA functional domains, purified domain polypeptides, assessed DNAbinding and ATPase activities in vitro and characterized the role of each functional domain in E. coli DNA repairAbbott Laboratories//Abbott Park, IllinoisResearch Technician, Hepatitis Business Unit, Research and Development, 1983-1984• Assisted in the development of an automated instrument for use in detecting blood-borne pathogens, e.g.,Hepatitis and HIV• Troubleshot false positives identified in biological assays• Collaborated with project engineers to improve instrument performance prior to field studiesUniversity of Michigan//Ann Arbor, MichiganTeaching Assistant, Department of Biology, Spring of 1982• Taught a laboratory course in basic microbiological methodsArgonne National Laboratory//Argonne, IllinoisStudent Aide, Department of Biology in Medicine, Summers of 1979 and 1980• Provided technical assistance on environmental impact studies related to an experimental fluidized bed coalcombustorSCIENTIFIC PUBLICATIONS AND ABSTRACTS Bourette R.P., Arnaud S., Myles G.M., Blanchet J.P., Rohrschneider L.R., and Mouchiroud G. (1998) Mona, aNovel Hematopoietic-Specific Adapter Interacting with the Macrophage-Colony-Stimulating Factor Receptor isImplicated in Monocyte/Macrophage Development. EMBO Journal 17(24):7273-81. Bourette, R.P., Myles, G.M., Choi, J.L., and Rohrschneider, L.R. (1997) Sequential Activation ofPhosphatidylinositol 3-Kinase and Phospholipase C-Gamma2 by the M-CSF Receptor is Necessary forDifferentiation Signaling. EMBO Journal 16(19):5880-93. Rohrschneider, L.R., Bourette, R.P., Lioubin, M.N., Algate, P.A., Myles, G.M., and Carlberg, K. (1997)Growth and Differentiation Signals Regulated by the M-CSF Receptor. Molecular Reproduction andDevelopment 46(1):96-103. Bourette, R.P., Myles, G.M., Carlberg, K., Chen, A.R., and Rohrschneider, L.R. (1995) Uncoupling of theProliferation and Differentiation Signals Mediated by the Murine Macrophage Colony-Stimulating FactorExpressed in Myeloid FDC-P1 Cells. Cell Growth and Differentiation 6(6):631-45. Lioubin, M.N., Myles, G.M., Carlberg, K., and Rohrschneider, L.R. (1994) Shc, Grb2, Sos1, and a 150-kilodalton Tyrosine-Phosphorylated Protein form Complexes with Fms in Hematopoietic Cells. Molecular andCellular Biology 14(9):5682-91. Myles, G.M., Brandt, C.S., Carlberg, K., and Rohrschneider, L.R. (1994) Tyrosine 569 in the c-FmsJuxtamembrane Domain is Essential for Kinase Activity and Macrophage Colony-Stimulating Factor-DependentInternalization. Molecular and Cellular Biology 14(7):4843-54. Lioubin, M.N., Myles, G.M., Carlberg, K., and Rohrschneider, L.R. (1994) SHC, Grb2, SOS1, and a Novel150 kDa Tyrosine Phosphorylated Protein form Complexes with Fms in Hematopoietic Cells. Tenth AnnualMeeting on Oncogenes, Foundation for Advanced Cancer Studies, Inc. Carlberg, K., Lioubin, M.N., Myles, G.M., and Rohrschneider, L.R. (1994) Tyrosine 807 in Murine c-Fms hasa Role in Regulating both Receptor Tyrosine Phosphorylation and Substrate Interactions. Tenth Annual Meetingon Oncogenes, Foundation for Advanced Cancer Studies, Inc. Bourette, R.P., Myles, G.M., Carlberg, K., and Rohrschneider, L.R. (1994) Mutation of Tyrosine 807Abrogates the Differentiation but not the Proliferation Signal of the Murine M-CSF Receptor Expressed inMyeloid FDC-P1 cells. Tenth Annual Meeting on Oncogenes, Foundation for Advanced Cancer Studies, Inc. Wang, Z.E., Myles, G.M., Brandt, C.S., Lioubin, M.N., and Rohrschneider, L.R. (1993) Identification of theLigand-Binding Regions in the Macrophage Colony-Stimulating Factor Receptor Extracellular Domain. Molecularand Cellular Biology 13(9):5348-59.
  • 6. Myles, G.M., Brandt, C.S., and Rohrschneider, L.R. (1992) Identification of a Domain in the c-FmsCytoplasmic Domain Essential for M-CSF-Dependent Internalization. Eighth Annual Meeting on Oncogenes.Foundation for Advanced Cancer Studies, Inc. Rohrschneider, L.R., Wang, Z., Myles, G.M., and Brandt, C.S. (1992) Identification of the Ligand BindingRegion on the Murine M-CSF Receptor Extracellular Domain, and a Cytoplasmic Sequence Necessary forInternalization. The Biochemical Society 38th Harden Conference. Myles, G.M. and Sancar, A. (1991) Isolation and Characterization of Functional Domains of UvrA.Biochemistry 30(16):3834-38. Myles, G.M., Hearst, J.E., and Sancar, A. (1991) Site-Specific Mutagenesis of Conserved Residues withinWalker A and B Sequences of Escherichia coli UvrA Protein. Biochemistry 30(16):3824-24. Myles, G.M. and Sancar, A. (1989) DNA Repair. Chemical Research in Toxicology 2(4):197-226. Navaratnum, S., Myles, G.M., Strange, R.W., and Sancar, A. (1989) Evidence from Extended X-rayAbsorption Fine Structure and Site-Specific Mutagenesis for Zinc Fingers in UvrA Protein of Escherichia coli.Journal of Biological Chemistry 264:16067-71. Myles, G.M., Van Houten, B., and Sancar, A. (1987) Utilization of DNA Photolyase, Pyrimidine DimerEndonucleases, and Alkali Hydrolysis in the Analysis of Aberrant ABC Excinuclease Incisions Adjacent to UV-Induced DNA Photoproducts. Nucleic Acids Research 15(3):1227-43.